Reported covered position: Chief/Staff, Rep. Elise Stefanik (2015-2018); Leg Dir, Rep. Scott Tipton (2013-2014); Leg Dir, Rep. Todd Rokita (2011-2013); Spec Adv, Treas Dept (2007-2008); Spec Asst, Exec Off. of the Pres (2005-2006); Spec Asst, Off. of the VP (2002-2005)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
National Landslide Preparedness Act Reauthorization Act of 2025
Client: MANAGEMENT ASSOCIATION OF PRIVATE PHOTOGRAMMETRIST SURVEYORS · Firm: INVARIANT LLC
Support 3DEP reauthorization in H.R.2250/S.1626, National Landslide Preparedness Act Reauthorization Act of 2025; and H.R.4256/S.2245, Digital Coast Reauthorization Act of 2025; Earth MRI Reauthorization Act of 2026 (H.R.9640/S.4870).
Digital Coast Reauthorization Act of 2025
Client: MANAGEMENT ASSOCIATION OF PRIVATE PHOTOGRAMMETRIST SURVEYORS · Firm: INVARIANT LLC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ICEYE US, INC. via INVARIANT LLC
2026 · third_quarter · Q3
Educate Members and support the use of commercial satellite imaging for Earth mapping in H.R.8845, the Commerce, Justice, Science, and Related Agencies Appropriations Act of 2027; H.R.9171, the Department of the Interior, Environment, and Related Agencies Appropriations Act of 2027, and H.R.6938, the Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| ZURICH AMERICAN INSURANCE COMPANY |
| 13 |
| 2020–2022 |
| DENSITY INC. | 12 | 2020–2022 |
| MATTERMOST INC | 11 | 2023–2025 |
| SCALE | 11 | 2020–2022 |
| WORKDAY, INC. | 11 | 2019–2022 |
| LILT | 10 | 2021–2023 |
| Motorola Solutions, Inc. | 10 | 2019–2021 |
| SAILDRONE | 10 | 2021–2023 |
| VOLANSI | 9 | 2019–2021 |
| ANDURIL INDUSTRIES | 8 | 2019–2021 |
| EVENTBRITE, INC. | 8 | 2019–2020 |
| YELP | 8 | 2019–2020 |
| AIRBUS AMERICAS, INC. | 7 | 2022–2023 |
| CSC SERVICEWORKS | 6 | 2020–2021 |
| ICEYE US, INC. | 6 | 2021–2026 |
| LAMBDA, INC. | 6 | 2019–2020 |
| PALANTIR TECHNOLOGIES, INC. | 6 | 2023–2024 |
| URSA MAJOR | 6 | 2022–2023 |
| MARK43, INC. | 5 | 2021–2022 |
| MOTH+FLAME INC | 5 | 2020–2021 |
| DATAROBOT INC | 4 | 2022 |
| EMULATE, INC. | 3 | 2020 |
| MANAGEMENT ASSOCIATION OF PRIVATE PHOTOGRAMMETRIST SURVEYORS | 3 | 2024–2026 |
| SAP NATIONAL SECURITY SERVICES, INC. | 3 | 2019 |
| DSM-FIRMENICH | 2 | 2022 |
| NEWS/MEDIA ALLIANCE | 2 | 2020 |
| NSS LABS, INC. | 2 | 2019 |
| PREMISE | 2 | 2021–2023 |
| RTX CORPORATION | 2 | 2019–2020 |
| SARONIC TECHNOLOGIES | 2 | 2023 |
| FENIX GROUP, INC. | 1 | 2021 |
| SALESFORCE, INC. | 1 | 2026 |
| VSP | 1 | 2020 |
Support 3DEP reauthorization in H.R.2250/S.1626, National Landslide Preparedness Act Reauthorization Act of 2025; and H.R.4256/S.2245, Digital Coast Reauthorization Act of 2025; Earth MRI Reauthorization Act of 2026 (H.R.9640/S.4870).
Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026
Client: ICEYE US, INC. · Firm: INVARIANT LLC
Educate Members and support the use of commercial satellite imaging for Earth mapping in H.R.8845, the Commerce, Justice, Science, and Related Agencies Appropriations Act of 2027; H.R.9171, the Department of the Interior, Environment, and Related Agencies Appropriations Act of 2027, and H.R.6938, the Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: MANAGEMENT ASSOCIATION OF PRIVATE PHOTOGRAMMETRIST SURVEYORS · Firm: INVARIANT LLC
Support geospatial priorities in H.R.9171, the Department of the Interior, Environment, and Related Agencies Appropriations Act of 2027; H.R.8845, the Commerce, Justice, Science, and Related Agencies Appropriations Act of 2027; and H.R.8646, the Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act of 2027.
National Defense Authorization Act for Fiscal Year 2027
Client: MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) · Firm: INVARIANT LLC
Advocate for a robust fuel network to support the warfighter in H.R.8800/S.4784, the National Defense Authorization Act for Fiscal Year 2027.
National Defense Authorization Act for Fiscal Year 2027
Client: MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) · Firm: INVARIANT LLC
Advocate for a robust fuel network to support the warfighter in H.R.8800/S.4784, the National Defense Authorization Act for Fiscal Year 2027.
National Defense Authorization Act for Fiscal Year 2027
Client: MERLIN LABS · Firm: INVARIANT LLC
Educate Members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.8800/S.4784, the National Defense Authorization Act for Fiscal Year 2027, and the H.R. 9495, the Department of Defense Appropriations Act of 2027.
National Defense Authorization Act for Fiscal Year 2027
Client: MERLIN LABS · Firm: INVARIANT LLC
Educate Members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.8800/S.4784, the National Defense Authorization Act for Fiscal Year 2027, and the FY27 Department of Defense Appropriations Act.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client: MANAGEMENT ASSOCIATION OF PRIVATE PHOTOGRAMMETRIST SURVEYORS · Firm: INVARIANT LLC
Support geospatial priorities in H.R.9171, the Department of the Interior, Environment, and Related Agencies Appropriations Act of 2027; H.R.8845, the Commerce, Justice, Science, and Related Agencies Appropriations Act of 2027; and H.R.8646, the Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act of 2027.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client: ICEYE US, INC. · Firm: INVARIANT LLC
Educate Members and support the use of commercial satellite imaging for Earth mapping in H.R.8845, the Commerce, Justice, Science, and Related Agencies Appropriations Act of 2027; and H.R.9171, the Department of the Interior, Environment, and Related Agencies Appropriations Act of 2027.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client: ICEYE US, INC. · Firm: INVARIANT LLC
Educate Members and support the use of commercial satellite imaging for Earth mapping in H.R.8845, the Commerce, Justice, Science, and Related Agencies Appropriations Act of 2027; H.R.9171, the Department of the Interior, Environment, and Related Agencies Appropriations Act of 2027, and H.R.6938, the Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026.
Department of the Interior, Environment, and Related Agencies Appropriations Act, 2027
Client: ICEYE US, INC. · Firm: INVARIANT LLC
Educate Members and support the use of commercial satellite imaging for Earth mapping in H.R.8845, the Commerce, Justice, Science, and Related Agencies Appropriations Act of 2027; H.R.9171, the Department of the Interior, Environment, and Related Agencies Appropriations Act of 2027, and H.R.6938, the Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026.
Department of the Interior, Environment, and Related Agencies Appropriations Act, 2027
Client: MANAGEMENT ASSOCIATION OF PRIVATE PHOTOGRAMMETRIST SURVEYORS · Firm: INVARIANT LLC
Support geospatial priorities in H.R.9171, the Department of the Interior, Environment, and Related Agencies Appropriations Act of 2027; H.R.8845, the Commerce, Justice, Science, and Related Agencies Appropriations Act of 2027; and H.R.8646, the Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act of 2027.
Department of the Interior, Environment, and Related Agencies Appropriations Act, 2027
Client: ICEYE US, INC. · Firm: INVARIANT LLC
Educate Members and support the use of commercial satellite imaging for Earth mapping in H.R.8845, the Commerce, Justice, Science, and Related Agencies Appropriations Act of 2027; and H.R.9171, the Department of the Interior, Environment, and Related Agencies Appropriations Act of 2027.
Educate Members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.8800/S.4784, the National Defense Authorization Act for Fiscal Year 2027, and the H.R. 9495, the Department of Defense Appropriations Act of 2027.
Earth MRI Reauthorization Act of 2026
Client: MANAGEMENT ASSOCIATION OF PRIVATE PHOTOGRAMMETRIST SURVEYORS · Firm: INVARIANT LLC
Support 3DEP reauthorization in H.R.2250/S.1626, National Landslide Preparedness Act Reauthorization Act of 2025; and H.R.4256/S.2245, Digital Coast Reauthorization Act of 2025; Earth MRI Reauthorization Act of 2026 (H.R.9640/S.4870).
National Landslide Preparedness Act Reauthorization Act of 2025
Client: MANAGEMENT ASSOCIATION OF PRIVATE PHOTOGRAMMETRIST SURVEYORS · Firm: INVARIANT LLC
Support 3DEP reauthorization in H.R.2250/S.1626, National Landslide Preparedness Act Reauthorization Act of 2025; and H.R.4256/S.2245, Digital Coast Reauthorization Act of 2025; Earth MRI Reauthorization Act of 2026 (H.R.9640/S.4870).
A bill to amend the Digital Coast Act to improve the acquisition, integration, and accessibility of data of the Digital Coast program and to extend the program.
Client: MANAGEMENT ASSOCIATION OF PRIVATE PHOTOGRAMMETRIST SURVEYORS · Firm: INVARIANT LLC
Support 3DEP reauthorization in H.R.2250/S.1626, National Landslide Preparedness Act Reauthorization Act of 2025; and H.R.4256/S.2245, Digital Coast Reauthorization Act of 2025; Earth MRI Reauthorization Act of 2026 (H.R.9640/S.4870).
National Defense Authorization Act for Fiscal Year 2027
Client: MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) · Firm: INVARIANT LLC
Advocate for a robust fuel network to support the warfighter in H.R.8800/S.4784, the National Defense Authorization Act for Fiscal Year 2027.
National Defense Authorization Act for Fiscal Year 2027
Client: MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) · Firm: INVARIANT LLC
Advocate for a robust fuel network to support the warfighter in H.R.8800/S.4784, the National Defense Authorization Act for Fiscal Year 2027.
National Defense Authorization Act for Fiscal Year 2027
Client: MERLIN LABS · Firm: INVARIANT LLC
Educate Members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.8800/S.4784, the National Defense Authorization Act for Fiscal Year 2027, and the H.R. 9495, the Department of Defense Appropriations Act of 2027.
National Defense Authorization Act for Fiscal Year 2027
Client: MERLIN LABS · Firm: INVARIANT LLC
Educate Members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.8800/S.4784, the National Defense Authorization Act for Fiscal Year 2027, and the FY27 Department of Defense Appropriations Act.
Earth MRI Reauthorization Act of 2026
Client: MANAGEMENT ASSOCIATION OF PRIVATE PHOTOGRAMMETRIST SURVEYORS · Firm: INVARIANT LLC
Support 3DEP reauthorization in H.R.2250/S.1626, National Landslide Preparedness Act Reauthorization Act of 2025; and H.R.4256/S.2245, Digital Coast Reauthorization Act of 2025; Earth MRI Reauthorization Act of 2026 (H.R.9640/S.4870).
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
Client: ICON TECHNOLOGY, INC. · Firm: INVARIANT LLC
Support the use of advanced construction technology in the Department of Defense; support funding in the H.R.3838, Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026; S.2296, National Defense Authorization Act for Fiscal Year 2026; H.R.4016/S.2572, Department of Defense Appropriations Act; and H.R. 3944 and Senate, Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026.
Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026
Client: ICON TECHNOLOGY, INC. · Firm: INVARIANT LLC
Support the use of advanced construction technology in the Department of Defense; support funding in the H.R.3838, Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026; S.2296, National Defense Authorization Act for Fiscal Year 2026; H.R.4016/S.2572, Department of Defense Appropriations Act; and H.R. 3944 and Senate, Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026.
Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026
Client: ICON TECHNOLOGY, INC. · Firm: INVARIANT LLC
Support the use of advanced construction technology in H.R.5342/S.2354, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; S.933, NASA Transition Act of 2025, and H.R. 3944 and Senate, Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026.
Department of Defense Appropriations Act, 2026
Client: ICON TECHNOLOGY, INC. · Firm: INVARIANT LLC
Support the use of advanced construction technology in the Department of Defense; support funding in the H.R.3838, Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026; S.2296, National Defense Authorization Act for Fiscal Year 2026; H.R.4016/S.2572, Department of Defense Appropriations Act; and H.R. 3944 and Senate, Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026.
Department of Defense Appropriations Act, 2026
Client: ICON TECHNOLOGY, INC. · Firm: INVARIANT LLC
Support the use of advanced construction technology in the Department of Defense; support funding in P.L. 119-60, the National Defense Authorization Act for Fiscal Year 2026; H.R.4016/S.2572, Department of Defense Appropriations Act; and P.L. 119-37, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026.
Educate Members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in the H.R.4016/S.2572, Department of Defense Appropriations Act, 2026.
Educate Members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.4016/S.2572, the Department of Defense Appropriations Act, 2026.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: ICON TECHNOLOGY, INC. · Firm: INVARIANT LLC
Support the use of advanced construction technology in H.R.5342/S.2354, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; S.933, NASA Transition Act of 2025; and P.L. 119-37, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: ICON TECHNOLOGY, INC. · Firm: INVARIANT LLC
Support the use of advanced construction technology in H.R.5342/S.2354, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; S.933, NASA Transition Act of 2025, and H.R. 3944 and Senate, Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026.
National Defense Authorization Act for Fiscal Year 2026
Client: ICON TECHNOLOGY, INC. · Firm: INVARIANT LLC
Support the use of advanced construction technology in the Department of Defense; support funding in the H.R.3838, Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026; S.2296, National Defense Authorization Act for Fiscal Year 2026; H.R.4016/S.2572, Department of Defense Appropriations Act; and H.R. 3944 and Senate, Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: ICON TECHNOLOGY, INC. · Firm: INVARIANT LLC
Support the use of advanced construction technology in H.R.5342/S.2354, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; S.933, NASA Transition Act of 2025, and H.R. 3944 and Senate, Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: ICON TECHNOLOGY, INC. · Firm: INVARIANT LLC
Support the use of advanced construction technology in H.R.5342/S.2354, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; S.933, NASA Transition Act of 2025; and P.L. 119-37, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026.
Educate Members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.4016/S.2572, the Department of Defense Appropriations Act, 2026.
Department of Defense Appropriations Act, 2026
Client: ICON TECHNOLOGY, INC. · Firm: INVARIANT LLC
Support the use of advanced construction technology in the Department of Defense; support funding in the H.R.3838, Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026; S.2296, National Defense Authorization Act for Fiscal Year 2026; H.R.4016/S.2572, Department of Defense Appropriations Act; and H.R. 3944 and Senate, Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026.
Department of Defense Appropriations Act, 2026
Client: ICON TECHNOLOGY, INC. · Firm: INVARIANT LLC
Support the use of advanced construction technology in the Department of Defense; support funding in P.L. 119-60, the National Defense Authorization Act for Fiscal Year 2026; H.R.4016/S.2572, Department of Defense Appropriations Act; and P.L. 119-37, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026.
Educate Members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in the H.R.4016/S.2572, Department of Defense Appropriations Act, 2026.
Support the use of advanced construction technology in NASA; support Space Technology Mission Directorate funding in the FY 2026 Commerce, Justice, Science Appropriations and S.933, NASA Transition Act of 2025.
Support the use of advanced construction technology in H.R.5342/S.2354, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; S.933, NASA Transition Act of 2025, and H.R. 3944 and Senate, Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026.
Support the use of advanced construction technology in H.R.5342/S.2354, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; S.933, NASA Transition Act of 2025; and P.L. 119-37, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Making Insulin Affordable for All Children Act
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Drug Price Transparency in Medicaid Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
National Defense Authorization Act for Fiscal Year 2024
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on pharmacy issues related to TRICARE and H.R. 2670, S.2226 Fiscal Year 2024 National Defense Authorization Act.
Pharmacy Benefits Manager Accountability Act
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information.
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Ensuring Access to Lifesaving Drugs Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Lowering Drug Costs for American Families Act
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Expanding Seniors' Access to Lower Cost Medicines Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
To amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes.
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) · Firm: INVARIANT LLC
Advocate for a robust fuel network to support the warfighter in H.R. 8070, FY 2025 National Defense Authorization Act and Senate FY 2025 National Defense Authorization Act.
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) · Firm: INVARIANT LLC
Advocate for a robust fuel network to support the warfighter in H.R.8070, the FY 2025 National Defense Authorization Act, and Senate FY 2025 National Defense Authorization Act.
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate lawmakers on pharmacy issues related to TRICARE and H.R. 8070, the Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year.
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate lawmakers on pharmacy issues related to TRICARE and H.R. 8070, the Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year.
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate lawmakers on pharmacy issues related to TRICARE and H.R. 8070, the Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year.
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) · Firm: INVARIANT LLC
Advocate for a robust fuel network to support the warfighter in H.R.8070 / S.2226, FY 2025 National Defense Authorization Act.
Telehealth Benefit Expansion for Workers Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Educate members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.8774 / S.4921, FY 2025 Department of Defense Appropriations Act
Department of Defense Appropriations Act, 2025
Client: ICON TECHNOLOGY, INC. · Firm: INVARIANT LLC
Support the use of advanced construction technology in the Department of Defense; support funding in H.R.8774 / S.4921, FY 2025 Department of Defense Appropriations Act.
Department of Defense Appropriations Act, 2025
Client: MATTERMOST, INC. · Firm: INVARIANT LLC
Advocate for funding to provide the Air Force secure collaboration platforms in H.R.8774 / S.4921, the FY 2025 Department of Defense Appropriations Act.
Department of Defense Appropriations Act, 2025
Client: ICON TECHNOLOGY, INC. · Firm: INVARIANT LLC
Support the use of advanced construction technology in the Department of Defense and support funding in H.R.8774 / S.4921, the FY 2025 Department of Defense Appropriations Act.
Department of Defense Appropriations Act, 2025
Client: MATTERMOST, INC. · Firm: INVARIANT LLC
Advocate for funding to provide the Air Force secure collaboration platforms in H.R.8774 / S.4921, FY 2025 Department of Defense Appropriations Act.
Department of Defense Appropriations Act, 2025
Client: MATTERMOST, INC. · Firm: INVARIANT LLC
Advocate for funding to provide the Air Force secure collaboration platforms in H.R. 8774, FY 2025 Department of Defense Appropriations Act and Senate FY 2025 Department of Defense Appropriations Act.
Educate members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.8774 / S.4921, the FY 2025 Department of Defense Appropriations Act.
Educate members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R. 8774, FY 2025 Department of Defense Appropriations Act and Senate FY 2025 Department of Defense Appropriations Act.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Prescription Pricing for the People Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Pharmacy Benefit Manager Transparency Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
2026 · third_quarter · Q3
Support 3DEP reauthorization in H.R.2250/S.1626, National Landslide Preparedness Act Reauthorization Act of 2025; and H.R.4256/S.2245, Digital Coast Reauthorization Act of 2025; Earth MRI Reauthorization Act of 2026 (H.R.9640/S.4870).
Support geospatial priorities in H.R.9171, the Department of the Interior, Environment, and Related Agencies Appropriations Act of 2027; H.R.8845, the Commerce, Justice, Science, and Related Agencies Appropriations Act of 2027; and H.R.8646, the Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act of 2027.
Filing targets: HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE
SALESFORCE, INC. via INVARIANT LLC
2026 · third_quarter · Q3
Inform policymakers on defense modernization, AI, cybersecurity, and mission readiness developments across the national security community.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2026 · third_quarter · Q3
Advocate for a robust fuel network to support the warfighter in H.R.8800/S.4784, the National Defense Authorization Act for Fiscal Year 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Educate Members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.8800/S.4784, the National Defense Authorization Act for Fiscal Year 2027, and the H.R. 9495, the Department of Defense Appropriations Act of 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ICEYE US, INC. via INVARIANT LLC
2026 · second_quarter · Q2
Educate Members and support the use of commercial satellite imaging for Earth mapping in H.R.8845, the Commerce, Justice, Science, and Related Agencies Appropriations Act of 2027; and H.R.9171, the Department of the Interior, Environment, and Related Agencies Appropriations Act of 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Educate Members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.8800/S.4784, the National Defense Authorization Act for Fiscal Year 2027, and the FY27 Department of Defense Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2026 · second_quarter · Q2
Advocate for a robust fuel network to support the warfighter in H.R.8800/S.4784, the National Defense Authorization Act for Fiscal Year 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Educate Members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in the FY27 National Defense Authorization Act and FY27 Department of Defense Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2026 · first_quarter · Q1
Advocate for a robust fuel network to support the warfighter.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ICON TECHNOLOGY, INC. via INVARIANT LLC
2025 · fourth_quarter · Q4
Support the use of advanced construction technology in the Department of Defense; support funding in P.L. 119-60, the National Defense Authorization Act for Fiscal Year 2026; H.R.4016/S.2572, Department of Defense Appropriations Act; and P.L. 119-37, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026.
Support the use of advanced construction technology in H.R.5342/S.2354, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; S.933, NASA Transition Act of 2025; and P.L. 119-37, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Q4
Educate Members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.4016/S.2572, the Department of Defense Appropriations Act, 2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2025 · fourth_quarter · Q4
Advocate for a robust fuel network to support the warfighter.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Q3
Educate Members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in the H.R.4016/S.2572, Department of Defense Appropriations Act, 2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2025 · third_quarter · Q3
Advocate for a robust fuel network to support the warfighter.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ICON TECHNOLOGY, INC. via INVARIANT LLC
2025 · third_quarter · Q3
Support the use of advanced construction technology in the Department of Defense; support funding in the H.R.3838, Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026; S.2296, National Defense Authorization Act for Fiscal Year 2026; H.R.4016/S.2572, Department of Defense Appropriations Act; and H.R. 3944 and Senate, Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026.
Support the use of advanced construction technology in H.R.5342/S.2354, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; S.933, NASA Transition Act of 2025, and H.R. 3944 and Senate, Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MATTERMOST, INC. via INVARIANT LLC
2025 · second_quarter · Q2
Advocate for funding to provide the Air Force secure collaboration platforms in P.L. 119-4, Full-Year Continuing Appropriations and Extensions Act, 2025, and FY 2026 Department of Defense Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2025 · second_quarter · Q2
Advocate for a robust fuel network to support the warfighter.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ICON TECHNOLOGY, INC. via INVARIANT LLC
2025 · second_quarter · Q2
Support the use of advanced construction technology in the Department of Defense; support funding in the FY 2026 Department of Defense Appropriations Act and FY 2026 National Defense Authorization Act.
Support the use of advanced construction technology in NASA; support Space Technology Mission Directorate funding in the FY 2026 Commerce, Justice, Science Appropriations and S.933, NASA Transition Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Q2
Educate Members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in the FY 2026 Department of Defense Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MATTERMOST, INC. via INVARIANT LLC
2025 · first_quarter · Q1
Advocate for funding to provide the Air Force secure collaboration platforms in P.L. 119-4, Full-Year Continuing Appropriations and Extensions Act, 2025, and FY 2026 Department of Defense Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2025 · first_quarter · Q1
Advocate for a robust fuel network to support the warfighter.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ICON TECHNOLOGY, INC. via INVARIANT LLC
2025 · first_quarter · Q1
Support the use of advanced construction technology in the Department of Defense; support funding in the FY 2026 Department of Defense Appropriations Act.
Support the use of advanced construction technology in NASA; support Space Technology Mission Directorate funding inthe FY 2026 Commerce, Justice, Science Appropriations.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Q1
Educate members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in the FY 2026 Department of Defense Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Q4
Educate members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.8774 / S.4921, FY 2025 Department of Defense Appropriations Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ICON TECHNOLOGY, INC. via INVARIANT LLC
2024 · fourth_quarter · Q4
Support the use of advanced construction technology in NASA and support Space Technology Mission Directorate funding inH.R.9026 / S.4795, the FY 2025 Commerce, Justice, Science Appropriations Act.
Support the use of advanced construction technology in the Department of Defense; support funding in H.R.8774 / S.4921, FY 2025 Department of Defense Appropriations Act.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2024 · fourth_quarter · Q4
Educate lawmakers on pharmacy issues related to TRICARE and H.R. 8070, the Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year.
Monitor issues related to Medicare Part D and Medicare Advantage.
Educare lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; proposals related to telehealth; issues related to privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2024 · fourth_quarter · Q4
Advocate for a robust fuel network to support the warfighter in H.R.8070 / S.2226, FY 2025 National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MATTERMOST, INC. via INVARIANT LLC
2024 · fourth_quarter · Q4
Advocate for funding to provide the Air Force secure collaboration platforms in H.R.8774 / S.4921, FY 2025 Department of Defense Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Q3
Educate members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.8774 / S.4921, the FY 2025 Department of Defense Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2024 · third_quarter · Q3
Advocate for a robust fuel network to support the warfighter in H.R.8070, the FY 2025 National Defense Authorization Act, and Senate FY 2025 National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MATTERMOST, INC. via INVARIANT LLC
2024 · third_quarter · Q3
Discuss open source software and the national cyber workforce.
Advocate for funding to provide the Air Force secure collaboration platforms in H.R.8774 / S.4921, the FY 2025 Department of Defense Appropriations Act.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
MANAGEMENT ASSOCIATION OF PRIVATE PHOTOGRAMMETRIST SURVEYORS via INVARIANT LLC
2024 · third_quarter · Q3
Support geospatial priorities in fiscal year (FY) 2025 Interior, Environment, and Related Agencies Appropriations bill and Commerce, Justice, Science, and Related Agencies Appropriations bill.
Filing targets: HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE
ICON TECHNOLOGY, INC. via INVARIANT LLC
2024 · third_quarter · Q3
Support the use of advanced construction technology in NASA and support Space Technology Mission Directorate funding inH.R.9026 / S.4795, the FY 2025 Commerce, Justice, Science Appropriations Act.
Support the use of advanced construction technology in the Department of Defense and support funding in H.R.8774 / S.4921, the FY 2025 Department of Defense Appropriations Act.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2024 · third_quarter · Q3
Educate lawmakers on pharmacy issues related to TRICARE and H.R. 8070, the Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year.
Educare lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; proposals related to telehealth; issues related to privacy.
Monitor issues related to Medicare Part D and Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MANAGEMENT ASSOCIATION OF PRIVATE PHOTOGRAMMETRIST SURVEYORS via INVARIANT LLC
2024 · third_quarter · RR
Educate policymakers on mapping, surveying, GPS, and GIS data collection.
Educate policymakers on mapping, surveying, GPS, and GIS data collection.
CIGNA CORPORATION via INVARIANT LLC
2024 · second_quarter · Q2
Educate lawmakers on pharmacy issues related to TRICARE and H.R. 8070, the Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year.
Monitor issues related to Medicare Part D and Medicare Advantage.
Educare lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; proposals related to telehealth; issues related to privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MATTERMOST, INC. via INVARIANT LLC
2024 · second_quarter · Q2
Advocate for funding to provide the Air Force secure collaboration platforms in H.R. 8774, FY 2025 Department of Defense Appropriations Act and Senate FY 2025 Department of Defense Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2024 · second_quarter · Q2
Advocate for a robust fuel network to support the warfighter in H.R. 8070, FY 2025 National Defense Authorization Act and Senate FY 2025 National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Q2
Educate members on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R. 8774, FY 2025 Department of Defense Appropriations Act and Senate FY 2025 Department of Defense Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Q1
Promote domestically manufactured, autonomous flight platforms for DOD and support funding in FY 2024 and FY 2025 Department of Defense appropriations, FY 2025 National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2024 · first_quarter · Q1
Advocate for a robust fuel network to support the warfighter in the FY 2025 National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2024 · first_quarter · Q1
Advocate for funding to support information technology acquisition at the Department of Defense. Discuss the importance of funding for the procurement of software.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2024 · first_quarter · Q1
Advocate for funding to support information technology acquisition at the Department of Defense. Discuss the importance of funding for the procurement of software.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MATTERMOST, INC. via INVARIANT LLC
2024 · first_quarter · Q1
Advocate for funding to provide the Air Force secure collaboration platforms in FY 2025 House and Senate Department of Defense appropriations bills.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2024 · first_quarter · Q1
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
2023 · fourth_quarter · Q4
Educate members and the Administration on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.4365 / S.2587, FY 2024 Department of Defense appropriations bill.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2023 · fourth_quarter · Q4
Advocate for funding to support information technology acquisition at the Department of Defense. Discuss the importance of funding for the procurement of software.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AIRBUS AMERICAS, INC. via INVARIANT LLC
2023 · fourth_quarter · Q4
Educate policymakers on Airbuss presence in the U.S.; support sustainable aviation fuel and other carbon reduction efforts; discuss Federal Aviation Administration reauthorization legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SARONIC TECHNOLOGIES via INVARIANT LLC
2023 · fourth_quarter · Q4
Discuss benefits of autonomous surface vessels to enhance maritime awareness, extend reach, and improve survivability for naval operations.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
MATTERMOST, INC. via INVARIANT LLC
2023 · fourth_quarter · Q4
Advocate for funding to provide Space Force and Air Mobility Command secure collaboration platforms in H.R.4365 / S.2587, the FY 2024 Department of Defense Appropriations Act; H.R.2670, FY 2024 National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2023 · fourth_quarter · Q4
Advocate for a robust fuel network to support the warfighter in H.R.2670 / S.2226, FY 2024 National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2023 · fourth_quarter · Q4
Educare policymakers on issues related to the Improving Seniors Timely Access to Care Act of 2021; S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes; Issues related to pharmaceutical affordability and access in Medicare under H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act (Reps. Griffith and Carter); H.R. 5372, the Expanding Seniors Access to Lower Cost Medicines Act of 2023; H.R. 1352, the Increasing Access to Biosimilars Act; H.R. 5386, the Cutting Copays Act; and S. the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act).
SARONIC TECHNOLOGIES via INVARIANT LLC
2023 · fourth_quarter · RR
Autonomous surface vessels
2023 · third_quarter · Q3
Educate members and the Administration on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R.4365 / S.2587, FY 2024 Department of Defense appropriations bill.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2023 · third_quarter · Q3
Advocate for funding to support information technology acquisition at the Department of Defense.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2023 · third_quarter · Q3
Educate Congress on antitrust issues arising in critical national security contracts.
Advocate for a robust fuel network to support the warfighter in H.R.2670 / S.2226, FY 2024 National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2023 · third_quarter · Q3
Educare policymakers on issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule; issues related to S.1967, the Patients Before Middlemen (PBM)Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; issues related to pharmaceutical affordability and access in Medicare under H.R.2880, the Protecting Patients Against PBM Abuses Act; H.R.5376, the Share the Savings with Seniors Act; H.R.5385, the Medicare PBM Accountability Act; and H.R. 4881, and issues related to point-of-sale rebates in Part D LIS under the Medicare program
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127,the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the DRUG Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients(MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262,To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of th e 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; and issues related to Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for SeniorsAct; S.2254,the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822,the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disdosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health DATA Act;H.R. 4508, Hidden Fee Disdosure Act; H.R.3285 - Fairness for Patient Medications Act; S. Modernizing and Ensuring PBM Accountability Act.
PALO ALTO NETWORKS via INVARIANT LLC
2023 · third_quarter · 3T
Educate on cybersecurity threats to federal, state, and local governments and critical infrastructure. Advocate for funding to support cyber resilience in H.R.4367 / S.2625, FY 2024 Department of Homeland Security appropriations bill.
Educate Congress on cybersecurity threats to the Department of Defense; Advocate for cyber resilience and funding in H.R.2670 / S.2226, FY 2024 National Defense Authorization Act; H.R.4365/S.2587, FY 2024 Department of Defense appropriations bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Q3
Educate Members of Congress and the Administration on autonomous maritime vehicles and advocate for the use of innovative technology for ocean data collection, bathymetry, and maritime domain awareness. Advocated for funding and report language in the H.R.4821 / S.2605, FY 2024 Department of Interior appropriations bill; House draft / S.2321, FY 2024 Commerce, Justice, Science, and Related Agencies appropriations bill.
Educate Members of Congress on autonomous maritime vehicles and advocate for the use of innovative technology for ocean data collection, bathymetry, and maritime domain awareness in the H.R.4365 / S.2587, FY 2024 Department of Defense appropriations bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PREMISE via INVARIANT LLC
2023 · third_quarter · Q3
Support provisions in H.R.2670, FY 2024 National Defense Authorization Act, relevant to open source data collection and analysis. Support funding for the use of commercial data by the Department of Defense in H.R.4365 / S.2587, FY 2024 Department of Defense appropriations bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MATTERMOST, INC. via INVARIANT LLC
2023 · third_quarter · Q3
Advocate for funding to provide Space Force and Air Mobility Command secure collaboration platforms in H.R.4365 / S.2587, the FY 2024 Department of Defense appropriations act; H.R.2670, FY 2024 National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AIRBUS AMERICAS, INC. via INVARIANT LLC
2023 · third_quarter · Q3
Educate policymakers on Airbuss presence in the U.S.; support sustainable aviation fuel and other carbon reduction efforts; discuss Federal Aviation Administration reauthorization legislation.
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
ICON TECHNOLOGY, INC. via INVARIANT LLC
2023 · second_quarter · Q2
Support the use of advanced construction technology in NASA; support Space Technology Mission Directorate funding inthe FY 2024 Commerce-Justice-Science appropriations bill.
Support the use of advanced construction technology in the Department of Defense; support funding inthe Senate FY 2024 Department of Defense appropriations bill and H.R. 4365,and H.R. 2670 and Senate FY 2024 National Defense Authorization Act; Support adoption of innovative commercial technologies.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Vice President of the United States, SENATE
MATTERMOST, INC. via INVARIANT LLC
2023 · second_quarter · Q2
Advocate for funding to provide Space Force and Air Mobility Command secure collaboration platforms in the Senate FY24 Department of Defense appropriations Act and H.R.4365 and the H.R.2670 National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Q2
Educate Members of Congress and the Administration on autonomous maritime vehicles and advocate for the use of innovative technology for ocean data collection, bathymetry, and maritime domain awareness. Advocated for funding and report language in the FY 2024 Department of Interior appropriations bill and the House FY 2024 Commerce, Justice, Science, and Related Agencies appropriations bill and S.2321.
Educate Members of Congress on autonomous maritime vehicles and advocate for the use of innovative technology for ocean data collection, bathymetry, and maritime domain awareness in the Senate FY 2024 Department of Defense appropriations bill and H.R. 4365.
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE
LILT via INVARIANT LLC
2023 · second_quarter · Q2
Discuss and promote adaptive neural machine learning translation technologies; support funding in the H.R. 2670 and the Senate FY 2024 National Defense Authorization Act, and SenateFY 2024 Department of Defense appropriations bill and H.R. 4365 for translation technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AIRBUS AMERICAS, INC. via INVARIANT LLC
2023 · second_quarter · Q2
Educate Members of Congress on Airbuss presence in the U.S.; support sustainable aviation fuel and other carbon reduction efforts; discuss Federal Aviation Administration reauthorization legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Q2
Educate members and the Administration on domestically manufactured, autonomous flight platforms for use by the Department of Defense in the Senate FY 2024 Department of Defense appropriations bill and H.R. 4365.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2023 · second_quarter · Q2
Pharmacy issues related to TRICARE and the Fiscal Year 2024 National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2023 · second_quarter · Q2
Educate Congress on antitrust issues arising in critical national security contracts.
Advocate for a robust fuel network to support the warfighter in H.R.2670 / S.2226, the FY 2024 National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
2023 · second_quarter · Q2
Discuss importance of additive manufacturing for hypersonic engines and aerospace industry; support funding in H.R. 2670 and Senate FY 2024 National Defense Authorization Act, and Senate FY 2024 Department of Defense appropriations bill and H.R. 4365.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2023 · second_quarter · Q2
Advocate for funding to support information technology acquisition at the Department of Defense.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE
PEPSICO, INC. via INVARIANT LLC
2023 · second_quarter · Q2
Monitor the impact that immigration reform proposals would have on PepsiCo's workforce needs.
Educate Members of Congress about the importance of the food and beverage industry to the U.S. economy. Monitor the outcomes of the White House Conference on Hunger, Nutrition, and Health with regard to federal nutrition programs and standards.
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS via INVARIANT LLC
2023 · second_quarter · Q2
Educate Congress on cybersecurity threats to the Department of Defense; Advocate for cyber resilience and funding in H.R.2670 / S.2226 FY 2024 National Defense Authorization Act and H.R.4365 / S.2024 Department of Defense appropriations bill.
Educate on cybersecurity threats to federal, state, and local governments and critical infrastructure. Advocate for funding to support cyber resilience in H.R.4367 / Senate FY 2024 Department of Homeland Security appropriations bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2023 · first_quarter · Q1
Advocate for a robust fuel network to support the warfighter in the FY 2024 National Defense Authorization Act and the FY 2024 Department of Defense appropriations bill.
Educate Congress on antitrust issues arising in critical national security contracts.
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
2023 · first_quarter · Q1
Educate Members of Congress on autonomous marine vehicles and advocate for the use of innovative technology for ocean data collection, bathymetry, and maritime domain awareness in the FY 2024 Department of Interior appropriations bill and the FY 2024 Commerce, Justice, Science, and Related Agencies appropriations bill.
Educate Members of Congress on autonomous marine vehicles and advocate for the use of innovative technology for ocean data collection, bathymetry, and maritime domain awareness in the FY 2024 Department of Defense appropriations bill.
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
ICON TECHNOLOGY, INC. via INVARIANT LLC
2023 · first_quarter · Q1
Support the use of advanced construction technology in the Department of Defense; support funding inthe FY 2024 Department of Defense appropriations billand the FY 2024 National Defense Authorization Act.
Support the use of advanced construction technology in NASA; support Space Technology Mission Directorate funding inthe FY 2024 Commerce-Justice-Science appropriations bill.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
MATTERMOST, INC. via INVARIANT LLC
2023 · first_quarter · Q1
Advocate for funding to provide Space Force and Air Mobility Command secure collaboration platforms in the FY24 Department of Defense appropriations act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LILT via INVARIANT LLC
2023 · first_quarter · Q1
Discuss and promote adaptive neural machine learning translation technologies; support funding in the FY 2024 National Defense Authorization Act andFY 2024 Department of Defense appropriations bill for translation technologies.
Discuss and promote adaptive neural machine learning translation technologies.Support funding for the National Weather Service for translation technologies in the FY 2024 Commerce-Justice-Science appropriations bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Q1
Support initiatives with liquid rocket engine development in support of hypersonics and space launch, solid rocket motor development to support tactical weapons systems, and additive manufacturing for the mix of propulsion systems; support funding in FY 2024 NDAA and FY 2024 Department of Defense appropriations bill.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
AIRBUS AMERICAS, INC. via INVARIANT LLC
2023 · first_quarter · Q1
Educate Members of Congress and the Biden-Harris Administration on Airbuss presence in the U.S.; support sustainable aviation fuel and other carbon reduction efforts.
Filing targets: Energy, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Q1
Educate members and the Administration on domestically manufactured, autonomous flight platforms for use by the Department of Defense in the FY 2024 Department of Defense appropriations bill.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2023 · first_quarter · Q1
Advocate for funding to support information technology acquisition at the Department of Defense.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS via INVARIANT LLC
2023 · first_quarter · Q1
Educate Congress on cybersecurity threats to the Department of Defense; Advocate for funding in the FY 2024 National Defense Authorization Act and the 2024 Department of Defense appropriations bill.
Educate on cybersecurity threats to federal, state, and local governments and critical infrastructure. Advocate for funding to support cyber resilience in the FY 2024 Department of Homeland Security appropriations bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PEPSICO, INC. via INVARIANT LLC
2023 · first_quarter · Q1
Monitor the impact that immigration reform proposals would have on PepsiCos workforce needs.
Educate Members of Congress about the importance of the food and beverage industry to the U.S. economy. Monitor the outcomes of the White House Conference on Hunger, Nutrition, and Health with regard to federal nutrition programs and standards.
Filing targets: Agriculture, Dept of (USDA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2023 · first_quarter · Q1
Pharmacy issues related to TRICARE and the Fiscal Year 2024 National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MATTERMOST, INC. via INVARIANT LLC
2023 · first_quarter · RR
Space Force, Air Mobility Command, Department of Defense appropriations
ZURICH AMERICAN INSURANCE COMPANY via INVARIANT LLC
2022 · fourth_quarter · Q4
Monitor proposals related to legislation regarding apprenticeship programs and opportunities.
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE, Treasury, Dept of
2022 · fourth_quarter · Q4
Support initiatives with liquid rocket engine development in support of hypersonics and space launch, solid rocket motor development to support tactical weapons systems, and additive manufacturing for the mix of propulsion systems; support funding in H.R. 7776, the FY23 National Defense Authorization Act, and H.R. 8236/S.4663 FY 23 Department of Defense appropriations bill.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
MULTI SERVICE TECHNOLOGY SOLUTIONS, INC. (D/B/A TREVIPAY) via INVARIANT LLC
2022 · fourth_quarter · Q4
Advocate for a robust fuel network to support the warfighter. MonitorH.R.7776, the FY 2023 National Defense Authorization Act.
Educate Congress on critical national security government contracts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCALE via INVARIANT LLC
2022 · fourth_quarter · Q4
Educate Congress on the importance of data infrastructure to develop better artificial intelligence algorithms; advocate for artificial intelligence programs in, H.R.7776, the FY23 National Defense Authorization Act.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Q4
Educate Members of Congress on autonomous marine vehicles and advocate for the use of innovative technology for ocean data collection, bathymetry, and maritime domain awareness, including H.R. 8236/S. 4686 the FY23 Department of Interior appropriations bill, H.R. 8256/S.4664 the FY23 Commerce, Justice, Science, and Related Agencies appropriations bill, P.L. 117-58 the Infrastructure Investment and Jobs Act, and P.L. 117-169 the Inflation Reduction Act.
Educate Members of Congress on autonomous marine vehicles and advocate for the use of innovative technology for ocean data collection, bathymetry, and maritime domain awareness, including in H.R. 7776, FY23 National Defense Authorization Act, and H.R. 8236/S.4663, the FY23 Department of Defense appropriations bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PEPSICO, INC. via INVARIANT LLC
2022 · fourth_quarter · Q4
Monitor the impact that immigration reform proposals would have on PepsiCos workforce needs.
Educate Members of Congress about the importance of the food and beverage industry to the U.S. economy. Monitor the planning and implementation of the White House Conference on Hunger, Nutrition, and Health with regard to federal nutrition programs and standards.
Filing targets: Agriculture, Dept of (USDA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS via INVARIANT LLC
2022 · fourth_quarter · Q4
Educate Congress on cybersecurity threats to the Department of Defense; including network defense provisions in H.R. 7776, the FY 23 National Defense Authorization Act, and H.R. 8236/S.4664, the FY23 Department of Defense appropriations bill.
Educate on cybersecurity threats to federal, state, and local governments and critical infrastructure. Discuss funding that impacts cyber resilience, including H.R. 8257/S.4678, the FY23 Department of Homeland Security appropriations bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Q4
Educate members and the Administration on domestically manufactured, autonomous flight platforms for use by the Department of Defense in H.R. 7776, the FY23 National Defense Authorization Act, and H.R. 8236/S.4663, FY23 Department of Defense appropriations bill.
Filing targets: Air Force, Dept of, Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
LILT via INVARIANT LLC
2022 · fourth_quarter · Q4
Discuss and promote adaptive neural machine learning translation technologies; support funding in H.R. 7776, the FY23 National Defense Authorization Act, andH.R. 8236/S.4663,the FY 23 Department of Defense appropriations bill for translation technologies.
Discuss and promote adaptive neural machine learning translation technologies; support funding in H.R. 7776, the FY23 National Defense Authorization Act, H.R. 8236/S.4663, the FY 23 Department of Defense appropriations bill, and H.R. 8256/S.4664, the FY 23 Commerce-Justice-Science appropriationsbill for translation technologies.
Discuss and promote adaptive neural machine learning translation technologies,support funding for the National Weather Service for translation technologies in H.R. 8256/S.4664, the FY 23 Commerce-Justice-Science appropriations bill.
ICON TECHNOLOGY, INC. via INVARIANT LLC
2022 · fourth_quarter · Q4
Support the use of advanced construction technology in NASA; support Space Technology Mission Directorate funding inH.R. 8256/S.4664, theFY 23 Commerce-Justice-Science appropriations bill.
Support the use of advanced construction technology in the Department of Defense; support funding inH.R. 8236/S.4663, the FY 23 Department of Defense appropriations bill,and H.R. 7776, the FY23 National Defense Authorization Act.
Support the use of advanced construction technology in DOD, NASA, and other federal agencies; support funding inH.R. 8236/S.4663, the FY 23 Department of Defense appropriations bill.
DENSITY INC. via INVARIANT LLC
2022 · fourth_quarter · Q4
Monitor the General Service Administration's implementation of the Federal Assets Sale and Transfer Act (P.L. 114-287); monitor use of anonymous-by-design technology for building utilization rates and safe return to work.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2022 · fourth_quarter · Q4
Inform policymaker on pharmacy issues related to TRICARE and H.R. 7776, the "James M. Infohe National Defense Authorization Act for Fiscal Year 2023."
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Educate policymakers on pharmacy issues related to TRICARE and H.R. 2670, S.2226 Fiscal Year 2024 National Defense Authorization Act.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modernizing and Ensuring PBM Accountability Act; Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0).
Educate policymakers on pharmacy issues related to TRICARE and H.R. 2670, S.2226 Fiscal Year 2024 National Defense Authorization Act; issues related to removing barriers to biosimilar medicine access; issues relating to S. 464 / H.R. 2630, the Safe Step Act; related amendment to S. 1339, the Pharmacy Benefit Manager Reform Act; S. 2840,Bipartisan Primary Care and Health Workforce Act and issues related commercial insurance, telehealth, and pharmacy benefits; S. 3393 Support for Patients and Communities Reauthorization Act; and issues related to artificial intelligence and health care issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Educate policymakers on pharmacy issues related to TRICARE and H.R.2670, S.2226 Fiscal Year 2024 National Defense Authorization Act; issues related to P.L 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations; issues related to P.L 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign; issues related to removing barriers to biosimilar medicine access; issues related to insulin pricing, including S. 727, Insulin for All Act of 2023; S. 1269, INSULIN Act of 2023; S. 146, Cap Insulin Prices Now Act of 2023; HR 1488, Affordable Insulin Now Act; HR 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; issues related to mental health coverage, workforce, and mental health parity and the Behavioral Health Network and Directory Improvement Act and S. 2840, Bipartisan Primary Care and Health Workforce Act; and issues related commercial insurance, telehealth, and pharmacy benefits.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Army, Dept of (Other), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE